

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

September 14, 2021

<u>By E-Mail</u>

Kai H. E. Liekefett, Esq. Sidley Austin LLP 787 Seventh Avenue New York, NY 10019

Re: CytoDyn Inc. Response letter dated September 3, 2021 to comments issued on Soliciting Materials filed pursuant to Rule 14a-12 on August 19, 2021 File No. 000-49908

Dear Mr. Liekefett:

We have reviewed the responses to our comments on the above-captioned filing, and have the following comments.

- 1. We reissue prior comment 1 as it related to your statement that "...the Group is implicitly acknowledging that these posts violated federal securities laws." We do not believe you have provided sufficient support for your disclosure. Your response quoted explicit language used by the Group such that your belief as to what is being implied instead is superseded.
- 2. We reissue prior comment 2. We do not believe you have provided sufficient support for your disclosure. Your use of the phrase "hostile takeover," given your response, requires assumptions to be made that are not apparent.
- 3. We reissue prior comment 3. To the extent you continue referring to "dark money" as funding the dissidents' campaign, please include disclosure clarifying whether such funding or related activities appear to violate any proxy solicitation rules.
- 4. We reissue prior comment 4. Similar to our comment immediately above, to the extent you continue referring to Eisenberg Investments as "secretive," please include disclosure clarifying whether such funding or related activities appear to violate any proxy solicitation rules and describe the efforts you have made to obtain information about Eisenberg Investments.
- 5. We reissue prior comment 5. Thus, your response describing a specific chronology of events and your conclusions from such events should be clarified to note that votes or proxies may be revoked until such time as they are counted.
- 6. We reissue prior comment 6.

Kai H. E. Liekefett, Esq. Sidley Austin LLP September 14, 2021 Page 2

Please direct any questions to me at (202) 551-3619.

Sincerely,

<u>/s/ Daniel F. Duchovny</u> Daniel F. Duchovny Special Counsel Office of Mergers and Acquisitions